Skip to content
Catalyst brief · Phase 3 readout · 26 days

EMERALD: 1.0mg/kg/day PRAX-562 in Developmental and Epileptic Encephalopathy 1

Praxis Precision Medicines · $PRAX · built 19 Nov 2026 from 20 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's size, with plans to enrol 160 patients, and its 16-week measurement period, add to the reliability of the results, as a larger sample size and longer measurement period can provide more robust data. F2 F6
  • The trial has three study arms, which could allow for a comparison of different treatment regimens or a placebo control, further enhancing the validity of the results. F7
  • The fact that the main goal is focused on a specific patient population, Developmental and Epileptic Encephalopathy 1, helps to ensure that the results are relevant and applicable to this particular group. F1

Base rates

  • Historically, 53.9% of Phase 3 programmes in neurology moved on to a regulatory filing, which is an industry average and not a forecast for this trial. F13
  • The company has a record of delaying trials, with 43% of its active Phase 2 and 3 trials having their dates moved back by more than 6 months. F14
  • The DataCutoff timing model estimates this trial will finish close to its registry date, and the company has guided investors to expect data in Q4 2026. F11 F12
  • On average, PRAX's past trial-result days have seen an absolute share move of 33.6%, but this is just a historical average and not a forecast for this event. F15

Filings

  • The company has a cash position of $745M and a runway of about 28 months, which is after the trial's primary completion date F16 F17
  • There have been no open-market insider purchases or unplanned sales in the last 90 days F18
  • The company has reported two different FDA decision dates in SEC filings: 27 Dec 2026 and 29 Jan 2027 F19 F20

The case for

  • The trial's size and 16-week measurement period add to the reliability of the results, which could also support the trial's success. F2 F6

The case against

  • Nothing the facts support.

Open questions

  • Will the EMERALD trial meet its primary completion date of Dec 2026?
  • Will the trial's results show a significant reduction in seizure frequency in participants with DEEs compared to placebo?
  • How will the trial's outcome impact PRAX's regulatory filing and potential FDA approval?

9 AI sentences were removed by the fact check.

The facts

The trial

  • F1EMERALD is a Phase 3 trial of 1.0mg/kg/day PRAX-562 in Developmental and Epileptic Encephalopathy 1, sponsored by Praxis Precision Medicines (PRAX). source ↗
  • F2The trial plans to enrol 160 patients. source ↗

What counts as success

  • F3Main goal as written in the registry: To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placebo. source ↗
  • F4Blinding: quadruple blind. source ↗
  • F5Allocation: randomised. source ↗
  • F6The main goal is measured over: 16 weeks. source ↗
  • F7Number of study arms: 3. source ↗

When

  • F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
  • F10That date is 8.0 months later than the date first registered for this trial (Apr 2026). source ↗
  • F11In a filing of 9 Nov 2026 the company told investors to expect data in Q4 2026. This agrees with the registry date. source ↗
  • F12The DataCutoff timing model estimates this trial finishes close to its registry date. source ↗

Recruitment

Base rates

  • F13Historically 53.9% of Phase 3 programmes in neurology (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F1443% of PRAX's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗
  • F15PRAX has had 8 past trial-result days on record, with an average absolute share move of 33.6%. source ↗

Money, insiders and FDA

  • F16PRAX reported $745M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F17At the last 12 months' rate of spending (about $27M a month) that cash lasts about 28 months, to around Jan 2029, which is after the registry's primary completion date. source ↗
  • F18No open-market insider purchases or unplanned sales were reported in the last 90 days. source ↗
  • F19PRAX has reported an FDA decision date of 27 Dec 2026 in an SEC filing. source ↗
  • F20PRAX has reported an FDA decision date of 29 Jan 2027 in an SEC filing. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.